The existence of a circuit between two FPR2 agonists, ANXA1 and LXA4, has also been reported in more complex settings, such as those of obesity induced adipose inflammation, where chronic administration of LXA4 exerted tissue protection via switching macrophage phenotype while at the same time increasing tissue expression of ANXA1 (Borgeson et al., 2015). Here, ANXA1 is linked to inflammatory response.